Table 2.
Laboratory parameters, concomitant lipid-lowering and anti-hyperglycemic therapy at baseline according to prescribed PCSK9 inhibitor and diabetes status
| Characteristics | Total (n = 237) |
Alirocumab (n = 104) |
Evolocumab (n = 133) |
Without diabetes mellitus (n = 175) |
With diabetes mellitus type 2 (n = 54) |
|---|---|---|---|---|---|
| LDL-C (mg/dl) |
141 (117–188) n = 237 |
135 (114–181) n = 104 |
149 (118–191) n = 133 |
141 (117–188) n = 175 |
135 (110–178) n = 54 |
| Total cholesterol (mg/dl) |
229 (198–268) n = 216 |
210 (190–259) n = 94 |
240 (202–272) n = 122 |
230 (200–268) n = 163 |
216 (194–261) n = 47 |
| HDL-C (mg/dl) |
54 (45–65) n = 226 |
52 (44–63) n = 100 |
55 (46–67) n = 126 |
54 (46–67) n = 169 |
49 (42–60) n = 49 |
| Triglycerides (mg/dl) |
138 (99–215) n = 227 |
138 (102–255) n = 102 |
138 (97–197) n = 138 |
124 (97–199) n = 167 |
185 (134–249) n = 52 |
| Lp(a) (mg/dl) |
65 (25–101) n = 47 |
87 (71–114) n = 13 |
55 (18–90) n = 34 |
65 (23–114) n = 37 |
67 (46–89) n = 10 |
| HbA1c (mmol/mol) |
41 (37–49) n = 139 |
40 (37–49) n = 61 |
43 (37–50) n = 78 |
38 (36–40) n = 81 |
52 (48–57) n = 51 |
| Statins (n; %) | 70 (29.5) | 38 (36.5) | 32 (24.1) | 52 (29.7) | 16 (29.6) |
| Fluvastatin | 3 (1.3) | 2 (1.9) | 1 (0.8) | 2 (1.1) | 1 (1.9) |
| Pravastatin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Simvastatin | 5 (2.1) | 1 (1.0) | 4 (3.0) | 5 (2.9) | 0 (0) |
| Rosuvastatin | 29 (12.2) | 15 (14.4) | 14 (10.5) | 22 (12.6) | 5 (9.3) |
| Atorvastatin | 35 (14.8) | 21 (20.2) | 14 (10.5) | 25 (14.3) | 10 (18.5) |
| Ezetimibe | 94 (39.7) | 46 (44.2) | 48 (36.1) | 67 (38.3) | 22 (40.7) |
| Fibrates | 6 (2.5) | 2 (1.9) | 4 (3.0) | 2 (1.1) | 4 (7.4) |
| No lipid-lowering medication | 116 (48.9) | 44 (42.3) | 72 (54.1) | 89 (50.9) | 24 (44.4) |
| Antidiabetic treatment | |||||
| Metformin | 24 (10.1) | 13 (12.5) | 11 (8.3) | 0 (0) | 23 (42.6) |
| SGLT2 inhibitors | 5 (2.1) | 2 (1.9) | 3 (2.3) | 0 (0) | 4 (7.4) |
| DPP-4 inhibitors | 14 (5.9) | 7 (6.7) | 7 (5.3) | 0 (0) | 14 (25.9) |
| GLP-1 receptor agonists | 4 (1.7) | 0 (0) | 4 (3.0) | 0 (0) | 4 (7.4) |
| Sulfonylureas | 1 (0.4) | 0 (0) | 1 (0.8) | 0 (0) | 1 (1.9) |
| Pioglitazone | 2 (0.8) | 1 (1.0) | 1 (0.8) | 0 (0) | 2 (3.7) |
| Insulin therapy | 23 (9.7) | 9 (8.7) | 14 (10.5) | 0 (0) | 16 (29.6) |
| Diet only | 49 (20.7) | 22 (21.2) | 27 (20.3) | 0 (0) | 14 (25.9) |
Data are median (interquartile range) or number (%)
SGLT2 sodium-glucose co-transporter 2, GLP-1 Glucagon-like peptide 1, DPP-4 dipeptidyl-peptidase 4